Lion Biotechnologies Inc (OTCMKTS:LBIO), a biotech firm that is working on novel cancer immunotherapies, will be listed on the NASDAQ global market. The common shares of the company will begin trading on NASDAQ on February 26, 2015 under the ticker “LBIO”. The company’s common stock is listed with the same ticker on the OTCQB Marketplace.
The management view
Elma Hawkins, the CEO and President of Lion said that the listing of Lion on NASDAQ global market is a key achievement for Lion Biotechnologies Inc (OTCMKTS:LBIO). It will raise company’s profile in the investment community and will provide shareholders with a better platform for execution of their transactions.
Lion Biotechnologies is into the development of T cells for the treatment of various cancers. The lead product is a ready-to-infuse autologous ‘T-cell’ treatment that uses TIL for the cure of patients suffering from Metastatic Melanoma. The T-cell therapy is being assessed in the clinical studies at MD Anderson Cancer Center.
Lion Biotechnologies said that its board had appointed Ryan Maynard as a Director and Chair of the Audit Committee, effective immediately. Since 2010, Maynard has serviced as Chief Financial Officer and Executive Vice President of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). He also served on several senior positions since 2001.
Before he started his career with Rigel, he has served as Director of Finance and Accounting and Corporate Controller for Personify, Inc. Also, he was Controller with General Magic, Inc. He has held several positions including Senior Finance Manager at Siliconix, Inc. Earlier in his career, Maynard was associated with Ernst & Young, LLP. He completed his B.S. in accounting domain from Santa Clara University.
The management view
Elma Hawkins, the President and CEO of Lion Biotechnologies Inc (OTCMKTS:LBIO), said that the management is pleased to welcome Maynard on company’s board as a Director. Ryan has extensive experience in corporate financial management and reporting. Also, he has extraordinary track record in generating funds for public entities. His expertise and insights will be a valuable asset to the company.